science

Tezepelumab

Tezepelumab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Tezepelumab rather than just read about it. In short: Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma, developed and sold by AstraZeneca. Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.

Key takeaways

Tezepelumab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Tezepelumab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Tezepelumab from memory before moving on to harder problems.

Reference excerpt

Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma, developed and sold by AstraZeneca. Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation. Tezepelumab was approved for medical use in the United States in December 2021, and in the European Union in September 2022. The US Food and Drug Administration (FDA) considered it 2021 to be a first-in-class medication.

Medical uses Tezepelumab is indicated for the add-on maintenance treatment of people aged twelve years and older with severe asthma. In October 2025, it was approved for inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) for patients aged twelve years and older.

Side effects The most common side effects include arthralgia (joint pain) and pharyngitis (sore throat).

Pharmacodynamics Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation. Structural studies by X-ray crystallography showed that tezepelumab competes against a critical part of the TSLPR binding site on TSLP.

History In 2020, tezepelumab demonstrated efficacy compared to placebo for patients with severe, uncontrolled asthma in phase III trials. Two main studies including over 1,500 adults and adolescents with inadequately controlled asthma showed that tezepelumab was effective in reducing the number of severe asthma flare‑ups, as evaluated in two clinical trials of participants with severe asthma. All participants were taking their usual treatment for asthma and participants received new treatment with either tezepelumab or placebo. Neither the participants nor the investigators knew which treatment was given. The benefit of tezepelumab was assessed by measuring the frequency of asthma attacks (exacerbations) at the end of both 52 week trials in comparison to placebo. It was also studied for the treatment of chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria and eosinophilic esophagitis (EoE).

Society and culture

Legal status In December 2021, the US Food and Drug Administration (FDA) approved tezepelumab based on evidence from two clinical trials (NAVIGATOR and PATHWAY) of 1334 participants with severe asthma. The safety and efficacy of tezepelumab were evaluated in two clinical trials of participants with severe asthma. The trials were conducted in 24 countries (Argentina, Australia, Austria, Bulgaria, Brazil, Canada, Czech Republic, France, Germany, Hungary, Israel, Japan, Lithuania, Latvia, Russia, Saudi Arabia, Serbia, Slovakia, South Africa, South Korea, Taiwan, Ukraine, United States, and Vietnam). The FDA considered it 2021 to be a first-in-class medication. On 21 July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tezspire, intended as add-on treatment in adults and adolescents with severe asthma. The applicant for this medicinal product is AstraZeneca AB. Tezepelumab was approved for medical use in the European Union in September 2022.

See also dupilumab, anti IL-4 antibody to treat chronic rhinosinusitis with nasal polyps mepolizumab, anti–IL-5 to treat chronic rhinosinusitis with nasal polyps omalizumab anti–immunoglobulin E to treat chronic rhinosinusitis with nasal polyps stapokibart, anti IL-4 antibody to treat chronic rhinosinusitis with nasal polyps

References

External links Clinical trial number NCT02054130 for "Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma" at ClinicalTrials.gov Clinical trial number NCT03347279 for "Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)" at ClinicalTrials.gov

Illustrations

Worked examples

Example 1 — a first encounter with Tezepelumab

Start with the simplest possible case. Write down what Tezepelumab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tezepelumab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tezepelumab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tezepelumab

In research: Tezepelumab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Tezepelumab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Tezepelumab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Anti-asthmatic agents, Drugs developed by Amgen, Drugs developed by AstraZeneca, so understanding it makes those chapters shorter.
In everyday life: Look for Tezepelumab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Tezepelumab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Tezepelumab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Tezepelumab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Tezepelumab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tezepelumab in simple terms?

Why does Tezepelumab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tezepelumab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tezepelumab.